BioDelivery expects early 2009 approval for buccal fentanyl
This article was originally published in Scrip
Executive Summary
BioDelivery Sciences is expecting its buccal film formulation of fentanyl (Onsolis) to receive US approval in the first half of next year for breakthrough pain in opioid-tolerant patients with cancer, after receiving a US FDA complete response letter.